 HUTCHMED Limited said it had begun dosing its first patient in a phase III clinical trial of a treatment it is developing for a form of intestinal cancer. The study, taking place in China, will pair the companys SULANDA drug candidate with toripalimab and compare their performance with the standard of care, a product called FOLFIRI. 